EUCTR2005-005606-23-DK进行中（未招募）1 期
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder - MK-0594 Overactive Bladder Dose-Ranging Study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 530
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Postmenopausal women or men aged 40 to 74 (inclusive). Up to 10% of patients will be male. Average of = 8 micturitions per day, average of = 1 urge incontinence episodes per day, and predominance of urge incontinence episodes over stress incontinence episodes on 2 pre-randomization voiding diaries.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of diabetes insipidus, uncotrolled hyperglycemia or hypercalcemia, lower urinary tract symptoms associated with benign prostatic hypertrophy, active or current UTI, surgery to correct prolapsed uterus or stress incontinence.
研究者
相似试验
进行中（未招募）
1 期
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder - NDoveractove bladderMedDRA version: 6.1 Level: PT Classification code 10046494EUCTR2005-006201-12-ITMERCK SHARP DOHME530
进行中（未招募）
1 期
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder Estudio multicéntrico, doble ciego, aleatorizado, controlado con placebo y fármaco activo, en grupos paralelos y de dosificación del MK-0594 en pacientes con vejiga inestable - MK-0594 Overactive Bladder Dose-Ranging StudyOveractive BladderMedDRA version: 8.0 Level: LLT Classification code 10059617EUCTR2005-005606-23-ESMerck Sharp and Dohme de España530
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder - MK-0594 Overactive Bladder Dose-Ranging StudyOveractive BladderMedDRA version: 8.0Level: LLTClassification code 10059617EUCTR2005-005606-23-SEMerck Sharp & Dohme (Sweden) AB530
进行中（未招募）
1 期
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder - MK-0594 Overactive Bladder Dose-Ranging StudyOveractive BladderEUCTR2005-005606-23-DEMerck &Co.Inc.530
进行中（未招募）
1 期
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433Crohn's Disease (CD)MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-001225-41-IEAbbVie Deutschland GmbH & Co. KG747